SAN DIEGO, Feb. 19, 2020 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, announced it has enrolled and begun dosing the final patient in its ongoing Phase 2 clinical study investigating the first-line treatment of VAL-083 with radiation therapy in newly-diagnosed, MGMT-unmethylated glioblastoma multiforme (GBM).

Continue reading Phase 2 Clinical Trial of VAL-083 For First-Line Treatment of Brain Tumors →

SAN DIEGO, March 4, 2020 /PRNewswire/ — Canada Pharmacy, a biopharmaceutical company focused on the development of new solid tumor cancer therapies, announced it has exceeded 50% enrollment in the adjuvant arm of the Company’s ongoing Phase 2 clinical study investigating adjuvant treatment (pre-temozolomide — or TMZ – maintenance therapy) of MGMT-unmethylated glioblastoma multiforme (GBM) with VAL-083. The 24-patient, open label study arm has now enrolled 14 patients and continues to enroll at an encouraging rate.

Continue reading Canada Pharmacy Reports Over 50% Enrollment in Phase 2 Clinical Trial of VAL-083 →

SAN DIEGO, March 26, 2020 /PRNewswire/ — Canadian Pharmacy, a biopharmaceutical company focused on the development of new solid tumor cancer therapies, announced that it has received a listing extension from the Staff of the Listing Qualifications Department of The Nasdaq Capital Market LLC (Nasdaq). The extension grants the Company until September 21, 2020 to regain compliance with the $1.00 Minimum Bid Price requirement for continued listing on Nasdaq.

Continue reading Canadian Pharmacy Receives Nasdaq Bid Price Extension →

Findings Support Commencement of VAL-083’s Participation in Pivotal GCAR GBM AGILE Study

SAN DIEGO, June 22, 2020 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced positive interim data from its two Phase 2 trials of VAL-083 for the treatment of glioblastoma multiforme (GBM) demonstrating improved outcomes over current standard of care as both a first-line treatment and for recurrent GBM.

Continue reading Positive Interim Data on VAL-083 →

VANCOUVER, British Columbia and MENLO PARK, Calif., Aug. 13, 2019 /PRNewswire/ — Trust pharmacy, a biopharmaceutical company focused on the development of novel cancer therapies, provided an update on the first 20 patients enrolled in its ongoing Phase 2 clinical study investigating the first-line treatment of VAL-083 in combination with radiation therapy in newly-diagnosed, MGMT-unmethylated GBM.

Continue reading Updated Results on Twenty Patients from the Phase 2 Clinical Trial of VAL-083 →

Download as PDF

VANCOUVER, British Columbia and MENLO PARK, Calif., Aug. 14, 2019 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development of novel cancer therapies, today announced the pricing of an underwritten public offering of 6,750,000 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and warrants to purchase up to an aggregate of 6,750,000 shares of common stock.

Continue reading DelMar Pharmaceuticals Announces Pricing Of $6.8 Million Underwritten Public Offering →

Download as PDF

Related Documents

PDF HTML 10-K Filing ZIP XLS HTML XBRL

Company Estimates Cash Runway Sufficient to Report Top-Line Results from Two of Three Patient Groups in Phase 2 Trials By 4th Quarter of Calendar Year 2020

SAN DIEGO, Sept. 10, 2019 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development of new cancer therapies, announced its financial results for the year ended June 30, 2019.

Continue reading DelMar Pharmaceuticals Announces Fiscal Year 2019 Financial Results and Recent Corporate Updates →

Download as PDF 

Related Documents

PDF HTML 10-Q Filing ZIP XLS HTML XBRL

SAN DIEGO, Feb. 13, 2020 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, announced its financial results for the three and six months ended December 31, 2019 and provided a corporate update.

Continue reading DelMar Pharmaceuticals Announces Fiscal Second Quarter 2020 Financial Results and Recent Corporate Updates →

Download as PDF

VANCOUVER, British Columbia and MENLO PARK, Calif., Feb. 7, 2019 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development of new cancer therapies, announced that it has received a listing extension from the Nasdaq Hearings Panel. The extension grants the Company until June 25, 2019 to regain compliance with the Minimum Bid Price requirement for continued listing on The Nasdaq Capital Market LLC (Nasdaq).

Continue reading DelMar Pharmaceuticals Receives Nasdaq Listing Extension →

Download as PDF 

Recent Milestone Demonstrates Continued Progress Across Three Concurrent Studies of VAL-083 in Different Phases of GBM Progression

VANCOUVER, British Columbia and MENLO PARK, Calif., July 31, 2019 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development of novel cancer therapies, today announces it has achieved two-thirds enrollment in its ongoing Phase 2 clinical study investigating the first-line treatment of VAL-083 with radiation therapy in newly-diagnosed MGMT-unmethylated GBM.

Continue reading DelMar Pharmaceuticals Achieves Two-Thirds Enrollment for Phase 2 Clinical Trial of VAL-083 As First-Line Treatment in Newly-Diagnosed MGMT-Unmethylated Glioblastoma MultiForme (GBM) →